Compare ASTRAZENECA PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GLENMARK PHARMA ASTRAZENECA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 89.3 9.7 916.2% View Chart
P/BV x 27.1 1.2 2,170.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
GLENMARK PHARMA
Mar-19
ASTRAZENECA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278712 179.6%   
Low Rs883484 182.5%   
Sales per share (Unadj.) Rs228.4349.6 65.3%  
Earnings per share (Unadj.) Rs10.432.8 31.6%  
Cash flow per share (Unadj.) Rs16.344.3 36.7%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs98.8198.6 49.7%  
Shares outstanding (eoy) m25.00282.17 8.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 276.7%   
Avg P/E ratio x104.218.2 571.8%  
P/CF ratio (eoy) x66.413.5 492.9%  
Price / Book Value ratio x10.93.0 363.6%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m27,008168,625 16.0%   
No. of employees `0001.412.0 11.3%   
Total wages/salary Rs m1,53520,561 7.5%   
Avg. sales/employee Rs Th4,210.98,196.0 51.4%   
Avg. wages/employee Rs Th1,132.21,708.1 66.3%   
Avg. net profit/employee Rs Th191.1768.5 24.9%   
INCOME DATA
Net Sales Rs m5,71098,655 5.8%  
Other income Rs m1232,081 5.9%   
Total revenues Rs m5,833100,736 5.8%   
Gross profit Rs m46315,858 2.9%  
Depreciation Rs m1473,259 4.5%   
Interest Rs m03,346 0.0%   
Profit before tax Rs m43811,335 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1793,756 4.8%   
Profit after tax Rs m2599,250 2.8%  
Gross profit margin %8.116.1 50.4%  
Effective tax rate %40.833.1 123.2%   
Net profit margin %4.59.4 48.4%  
BALANCE SHEET DATA
Current assets Rs m3,20966,968 4.8%   
Current liabilities Rs m2,07040,211 5.1%   
Net working cap to sales %20.027.1 73.6%  
Current ratio x1.61.7 93.1%  
Inventory Days Days7283 86.8%  
Debtors Days Days3581 43.0%  
Net fixed assets Rs m79033,322 2.4%   
Share capital Rs m50282 17.7%   
"Free" reserves Rs m2,41955,770 4.3%   
Net worth Rs m2,46956,052 4.4%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m4,605132,888 3.5%  
Interest coverage xNM4.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.7 167.0%   
Return on assets %5.69.5 59.4%  
Return on equity %10.516.5 63.6%  
Return on capital %17.717.8 99.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30062,998 0.5%   
Fx outflow Rs m2,01522,859 8.8%   
Net fx Rs m-1,71540,140 -4.3%   
CASH FLOW
From Operations Rs m8813,242 0.7%  
From Investments Rs m-94-6,990 1.3%  
From Financial Activity Rs mNA-7,387 0.0%  
Net Cashflow Rs m-6-2,971 0.2%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 15.7 34.4 45.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 56,727 22.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

SUN PHARMA Surges by 6%; BSE HEALTHCARE Index Up 4.7% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

SUN PHARMA share price has surged by 6% and its current market price is Rs 470. The BSE HEALTHCARE is up by 4.7%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 6.3%) and ASTRAZENECA PHARMA (up 5.2%). The top losers are IPCA LABS (down 0.8%) and TORRENT PHARMA (down 0.9%).

LUPIN Surges by 13%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

LUPIN share price has surged by 13% and its current market price is Rs 798. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are LUPIN (up 12.7%) and DIVIS LABORATORIES (up 6.2%). The top losers are J.B.CHEMICALS (down 0.2%) and PROCTER & GAMBLE HEALTH (down 1.2%).

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS